The immune cells were at a 7 times higher ratio in lung samples from men than women, and may explain sex differences between ...

Among patients with pulmonary arterial hypertension treated with 72-week seralutinib, those deemed responders had more ...

Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief ...

Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

Two Groundbreaking Studies on Fluid Management: Pulmonary Artery Pressure Monitoring Falls Short, New Diuretic Insights Emerge ...

February is National Heart Health Awareness Month and during this month, The Hospitals of Providence is raising awareness of ...

The device has evolved from one aimed at just functional MR to a broader HF therapy. EMPOWER will provide more insights.

Lungpacer Medical today announced positive results from a Phase 1 clinical study evaluating its neurostimulation technology ...

Daxor (DXR) announces new studies from Duke University Medical Center and Yale School of Medicine, presented at the Technology and Heart ...